Ligand Pharmaceuticals (LGND) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to -$7.6 million.
- Ligand Pharmaceuticals' Other Gross PP&E Adjustments fell 631.55% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.6 million, marking a year-over-year decrease of 631.55%. This contributed to the annual value of $8.9 million for FY2024, which is 3575.26% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Other Gross PP&E Adjustments of -$7.6 million as of Q3 2025, which was down 631.55% from -$8.0 million recorded in Q2 2025.
- In the past 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments ranged from a high of $17.9 million in Q4 2022 and a low of -$32.1 million during Q3 2022
- In the last 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments had a median value of -$7.6 million in 2025 and averaged -$7.3 million.
- Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments showed a top increase of 29379.26% in 2021 and a maximum decrease of 29341.77% in 2021.
- Over the past 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments (Quarter) stood at $11.0 million in 2021, then surged by 63.51% to $17.9 million in 2022, then dropped by 23.06% to $13.8 million in 2023, then plummeted by 35.75% to $8.9 million in 2024, then tumbled by 185.78% to -$7.6 million in 2025.
- Its last three reported values are -$7.6 million in Q3 2025, -$8.0 million for Q2 2025, and -$800000.0 during Q1 2025.